• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of the mechanism of drug resistance in cancer stem cells regulated by actin cytoskeleton dynamics and therapeutic strategies based on this mechanism

Research Project

Project/Area Number 21K07131
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 50010:Tumor biology-related
Research InstitutionFujita Health University

Principal Investigator

Nobusue Hiroyuki  藤田医科大学, 腫瘍医学研究センター, 講師 (90525685)

Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywordsアクチン細胞骨格 / がん幹細胞 / 薬剤耐性 / 骨肉腫 / MKL1
Outline of Research at the Start

腫瘍組織は不均一な細胞集団により構成されており、特にがん幹細胞は化学療法抵抗性(薬剤耐性)を有しており、その特性はがんの根治を困難にするとともに、がん再発の主たる要因となっている。したがって、がん幹細胞の薬剤耐性を制御する分子機構の解明とその制御に基づくがん幹細胞を標的とした新規治療法の開発が切望されている。申請者らはごく最近、マウス骨肉腫モデルにおいて薬剤耐性を示す潜在的がん幹細胞を同定し、アクチン動態により制御される転写調節因子MKL1が骨肉腫幹細胞の薬剤耐性を制御するマスター因子として働くことを見出している。

Outline of Final Research Achievements

We previously established osteosarcoma-initiating (OSi) cells by overexpression of c-Myc in bone marrow stromal cells derived from Ink4a/Arf (-/-) mice. Osi cells are composed of two distinct clones: chemosensitive AX cells and chemoresistant AO cells. We found that AO cells survived after the doxorubicin treatment exhibited excessive actin polymerization and nuclear translocation of and transcriptional activation by MKL1 (megakaryoblastic leukemia 1) which is associated with actin cytoskeleton dynamics. In addition, depletion of MKL1 enhanced the sensitivity of AO cells to doxorubicin whereas, conversely, overexpression of MKL1 attenuated that of AX cells to doxorubicin. Furthermore, we found that inhibition of actin polymerization potentiated the antitumor activity of doxorubicin in human OS cell lines through inactivation of MKL1.These finding suggest thus that MKL1 acts as a key molecule in regulating the chemoresistance of OS cells.

Academic Significance and Societal Importance of the Research Achievements

本研究成果は、細胞骨格構成要素であるアクチンの動態を分子標的として制御することで、転写制御シグナルを変化させ、がん幹細胞の薬剤耐性を阻害し腫瘍抑制するという新規治療法の開発に繋がるものであり、学術的に新しい概念を生み出すだけでなく、社会的意義も極めて大きいと考える。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (11 results)

All 2023 2022 2021 Other

All Journal Article (4 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 4 results,  Open Access: 4 results) Presentation (4 results) (of which Int'l Joint Research: 1 results) Remarks (2 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] Growth Transformation of B Cells by Epstein-Barr Virus Requires <i>IMPDH2</i> Induction and Nucleolar Hypertrophy2023

    • Author(s)
      Sugimoto Atsuko、Watanabe Takahiro、Matsuoka Kazuhiro、Okuno Yusuke、Yanagi Yusuke、Narita Yohei、Mabuchi Seiyo、Nobusue Hiroyuki、Sugihara Eiji、Hirayama Masaya、Ide Tomihiko、Onouchi Takanori、Sato Yoshitaka、Kanda Teru、Saya Hideyuki、Iwatani Yasumasa、Kimura Hiroshi、Murata Takayuki
    • Journal Title

      Microbiology Spectrum

      Volume: 11 Issue: 4

    • DOI

      10.1128/spectrum.00440-23

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo2022

    • Author(s)
      Shimizu Takatsune、Sugihara Eiji、Takeshima Hideyuki、Nobusue Hiroyuki、Yamaguchi Rui、Yamaguchi-Iwai Sayaka、Fukuchi Yumi、Ushijima Toshikazu、Muto Akihiro、Saya Hideyuki
    • Journal Title

      Cells

      Volume: 11 Issue: 22 Pages: 3614-3614

    • DOI

      10.3390/cells11223614

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Regulatory roles of fibronectin and integrin α5 in reorganization of the actin cytoskeleton and completion of adipogenesis2022

    • Author(s)
      Uetaki Megumi、Onishi Nobuyuki、Oki Yoshinao、Shimizu Takatsune、Sugihara Eiji、Sampetrean Oltea、Watanabe Takashi、Yanagi Hisano、Suda Kiyoshi、Fujii Hiroya、Kano Koichiro、Saya Hideyuki、Nobusue Hiroyuki
    • Journal Title

      Molecular Biology of the Cell

      Volume: 33 Issue: 9

    • DOI

      10.1091/mbc.e21-12-0609

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] MEK inhibition preferentially suppresses anchorage‐independent growth in osteosarcoma cells and decreases tumors in vivo2021

    • Author(s)
      Shimizu Takatsune、Kimura Kiyomi、Sugihara Eiji、Yamaguchi‐Iwai Sayaka、Nobusue Hiroyuki、Sampetrean Oltea、Otsuki Yuji、Fukuchi Yumi、Saitoh Kaori、Kato Keiko、Soga Tomoyoshi、Muto Akihiro、Saya Hideyuki
    • Journal Title

      Journal of Orthopaedic Research

      Volume: - Issue: 12 Pages: 2732-2743

    • DOI

      10.1002/jor.25023

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] ROCK阻害剤ファスジルは治療抵抗性骨肉腫細胞において化学療法による抗腫瘍効果を高める2023

    • Author(s)
      信末博行、清水孝恒、上瀧 萌、住吉清香、近藤由佳、山田勢至、塚本徹哉、佐谷秀行
    • Organizer
      第82回日本癌学会学術総会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Therapeutic strategies based on actin cytoskeleton dynamics for targeting chemoresistant osteosarcoma stem cells2022

    • Author(s)
      信末博行, 清水孝恒, 高橋信博, 山口さやか, 杉原英志, 大西伸幸, 佐谷秀行
    • Organizer
      第12回 日米癌合同会議
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] Inhibition of MKL1 enhances the effects of anticancer drugs in chemoresistant osteosarcoma cells2022

    • Author(s)
      信末博行, 清水孝恒, 高橋信博, 山口さやか, 杉原英志, 大西伸幸, 佐谷秀行
    • Organizer
      第81回 日本癌学会学術総会
    • Related Report
      2022 Research-status Report
  • [Presentation] Therapeutic strategies based on actin cytoskeleton dynamics for targeting chemoresistant osteosarcoma stem cells2021

    • Author(s)
      信末博行, 清水孝恒, 高橋信博, 山口さやか, 杉原英志, 大西伸幸, 佐谷秀行
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Research-status Report
  • [Remarks] 藤田医科大学 腫瘍医学研究センター ホームページ

    • URL

      https://fcc.fujita-hu.ac.jp

    • Related Report
      2023 Annual Research Report
  • [Remarks] 藤田医科大学 がん医療研究センター ホームページ

    • URL

      https://fcc.fujita-hu.ac.jp/

    • Related Report
      2022 Research-status Report
  • [Patent(Industrial Property Rights)] 治療抵抗性がん細胞制御剤及び抗がん剤の抗腫瘍作用増強剤2021

    • Inventor(s)
      佐谷秀行, 信末博行
    • Industrial Property Rights Holder
      佐谷秀行, 信末博行
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2021-214001
    • Filing Date
      2021
    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi